Inhalation exposure to 2-ethyl-1-hexanol causes hepatomegaly and transient lipid accumulation without induction of peroxisome proliferator-activated receptor alpha in mice.

2-Ethyl-1-hexanol Hepatic enlargement Inhalation exposure Lipid droplet Peroxisome proliferator-activated receptor alpha (PPARα) Volatile organic compound (VOC)

Journal

Industrial health
ISSN: 1880-8026
Titre abrégé: Ind Health
Pays: Japan
ID NLM: 2985065R

Informations de publication

Date de publication:
29 Nov 2021
Historique:
pubmed: 1 10 2021
medline: 1 12 2021
entrez: 30 9 2021
Statut: ppublish

Résumé

2-Ethyl-1-hexanol (2EH) is a volatile organic compound known to cause sick building syndrome. However, 2EH-induced hepatotoxicity has been mainly evaluated in experiments orally administering 2EH as a metabolite of di(2-ethylhexyl) phthalate. To evaluate the hepatotoxicity risk of 2EH as an indoor air pollutant, we exposed 10-wk-old male ICR mice to 2EH by inhalation for 8 h/d, 5 d/wk for 3 months (0, 20, 60, or 150 ppm) or 6 months (0, 0.5, 10, or 100 ppm). In both experiments, relative liver weights significantly increased in the highest exposure groups. The 3-month exposure increased histopathological lipid droplets in the liver in a dose-dependent manner, hepatic triglyceride at all exposure levels, hepatic phospholipid at 150 ppm, and microsomal triglyceride transfer protein at 60 and 150 ppm; however, these changes were not observed following the 6-month of exposure. Following the 3-month exposure, alanine transaminase and peroxisomal bifunctional proteins, known markers of liver injury and peroxisome proliferation, respectively, remained unaltered. Therefore, in the present study, the inhalation concentration range of 2EH induced a toxic hypertrophic change, revealing a limited role of peroxisome proliferator-activated receptor alpha (PPARα). The liver weights may have presumably increased via a mechanism independent of PPARα activation.

Identifiants

pubmed: 34588381
doi: 10.2486/indhealth.2020-0252
pmc: PMC8655744
doi:

Substances chimiques

Hexanols 0
PPAR alpha 0
2-ethylhexanol XZV7TAA77P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-392

Références

Regul Toxicol Pharmacol. 2014 Oct;70(1):54-64
pubmed: 24912090
Fundam Appl Toxicol. 1996 May;31(1):29-41
pubmed: 8998951
Cell Mol Life Sci. 2004 Feb;61(4):393-416
pubmed: 14999402
Arch Toxicol. 2016 Aug;90(8):1949-58
pubmed: 27055686
Toxicol Ind Health. 1987 Jun;3(2):49-61
pubmed: 3617069
Biochem Pharmacol. 1978;27(19):2283-8
pubmed: 728182
Xenobiotica. 1975 Oct;5(10):625-36
pubmed: 1189459
Toxicology. 2005 Feb 1;207(1):149-63
pubmed: 15590130
Toxicol Appl Pharmacol. 1999 Dec 1;161(2):209-18
pubmed: 10581215
Neuropharmacology. 2005 Jun;48(8):1147-53
pubmed: 15910890
Arch Biochem Biophys. 1980 Aug;203(1):372-83
pubmed: 6773478
J Occup Health. 2007 May;49(3):172-82
pubmed: 17575397
Biol Chem. 2018 Oct 25;399(11):1237-1248
pubmed: 29924722
Fundam Appl Toxicol. 1996 Jan;29(1):31-9
pubmed: 8838637
PPAR Res. 2010;2010:
pubmed: 20936127
Biochem Biophys Res Commun. 2000 May 10;271(2):445-50
pubmed: 10799317
Arch Toxicol. 1992;66(5):321-6
pubmed: 1610294
Toxicol Lett. 1982 Mar;10(4):379-83
pubmed: 7089991
J Occup Health. 2019 Jan;61(1):19-35
pubmed: 30698348
Toxicol Sci. 2008 Oct;105(2):384-94
pubmed: 18593727
Toxicol Appl Pharmacol. 1978 Aug;45(2):497-504
pubmed: 705785
J Carcinog. 2004 May 24;3(1):9
pubmed: 15157275
Toxicol Pathol. 1998 Mar-Apr;26(2):240-6
pubmed: 9547862
Toxicol Appl Pharmacol. 1975 May;32(2):355-67
pubmed: 168667
J Pharmacol Exp Ther. 1989 Jan;248(1):176-81
pubmed: 2913270
Am Ind Hyg Assoc J. 1973 Nov;34(11):493-9
pubmed: 4770172
Shokuhin Eiseigaku Zasshi. 2015;56(2):42-8
pubmed: 25925075
Food Chem Toxicol. 1998 Mar;36(3):165-8
pubmed: 9609389
Environ Health Perspect. 1986 Mar;65:293-8
pubmed: 3086077
Nihon Koshu Eisei Zasshi. 2005 Dec;52(12):1021-31
pubmed: 16457196
J Biol Chem. 1957 May;226(1):497-509
pubmed: 13428781
Mol Cell Biol. 1995 Jun;15(6):3012-22
pubmed: 7539101
J Biol Chem. 1992 Jan 15;267(2):1027-33
pubmed: 1730632
J Environ Monit. 2009 Nov;11(11):2068-76
pubmed: 19890564
Int Arch Occup Environ Health. 1999 Oct;72(7):451-61
pubmed: 10541910
Arch Toxicol. 2005 Mar;79(3):147-54
pubmed: 15798888
J Biol Chem. 2005 Jan 14;280(2):1224-9
pubmed: 15537571
Food Chem Toxicol. 1995 Nov;33(11):971-8
pubmed: 7590545
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313

Auteurs

Takanari Wakayama (T)

Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Japan.
Department of Environmental Health, Nagoya City Public Health Research Institute, Japan.

Yuki Ito (Y)

Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Japan.

Mio Miyake (M)

Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Japan.

Karin Nomasa (K)

Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Japan.

Kiyoshi Sakai (K)

Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Japan.
Department of Environmental Health, Nagoya City Public Health Research Institute, Japan.

Naoko Oya (N)

Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Japan.
Research Fellow of Japan Society for the Promotion of Science, Japan.

Hirotaka Sato (H)

Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Japan.

Hiroyuki Ohno (H)

Department of Environmental Health, Nagoya City Public Health Research Institute, Japan.

Michihiro Kamijima (M)

Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH